Who owns VanEck Pharmaceutical ETF?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of PPH from SEC Form 13F filings across 149 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 149 institutions disclosed 6.2M shares of VanEck Pharmaceutical ETF worth $680.0M — about 71.6% of shares outstanding; the largest disclosed holder is GOLDMAN SACHS GROUP INC. Source: SEC Form 13F filings, parsed by EvidInvest.
149
13F holders
$680.0M
value, 2026 filers
71.6%
of shares outstanding (6.2M sh)
22
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of PPH's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | GOLDMAN SACHS GROUP INC | 1.2M | $128.9M | 0.0% | 13.6% | +19.6% |
| 2 | MORGAN STANLEY | 1.0M | $112.4M | 0.0% | 11.8% | +478.2% |
| 3 | UBS Group AG | 517,756 | $56.6M | 0.0% | 6% | +842.0% |
| 4 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 402,000 | $44.0M | 0.1% | 4.6% | -28.3% |
| 5 | BNP PARIBAS FINANCIAL MARKETS | 350,600 | $38.3M | 0.0% | 4% | -36.1% |
| 6 | J.Safra Asset Management Corp | 319,636 | $35.0M | 1.6% | 3.7% | +2.8% |
| 7 | CITIGROUP INC | 318,604 | $34.8M | 0.0% | 3.7% | +45.1% |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 281,661 | $30.8M | 0.0% | 3.2% | +234.5% |
| 9 | Avalon Trust Co | 263,830 | $28.8M | 1.8% | 3% | -1.4% |
| 10 | ADAMSBROWN WEALTH CONSULTANTS LLC | 154,114 | $16.9M | 3.2% | 1.8% | +3.6% |
| 11 | LPL Financial LLC | 118,058 | $12.9M | 0.0% | 1.4% | +5.2% |
| 12 | Miller Investment Management, LPNEW | 100,256 | $11.0M | 1.0% | 1.2% | new |
| 13 | ROYAL BANK OF CANADA | 95,470 | $10.4M | 0.0% | 1.1% | -73.6% |
| 14 | BANK OF AMERICA CORP /DE/ | 79,699 | $8.7M | 0.0% | 0.9% | -44.5% |
| 15 | Rye Brook Capital LLCNEW | 67,330 | $7.4M | 5.2% | 0.8% | new |
| 16 | WT Wealth Management | 53,786 | $5.9M | 1.6% | 0.6% | +6.8% |
| 17 | Qube Research & Technologies Ltd | 46,536 | $5.1M | 0.0% | 0.5% | +64.8% |
| 18 | Prime Capital Investment Advisors, LLC | 42,490 | $4.6M | 0.0% | 0.5% | -54.3% |
| 19 | Fluent Financial, LLCNEW | 38,992 | $4.3M | 1.5% | 0.4% | new |
| 20 | GTS SECURITIES LLC | 36,942 | $4.0M | 0.1% | 0.4% | -81.8% |
| 21 | Cetera Investment Advisers | 36,292 | $4.0M | 0.0% | 0.4% | -2.9% |
| 22 | JPMORGAN CHASE & CO | 36,112 | $4.0M | 0.0% | 0.4% | +923.3% |
| 23 | CITADEL ADVISORS LLC | 33,171 | $3.6M | 0.0% | 0.4% | -50.6% |
| 24 | Tower Research Capital LLC (TRC) | 31,350 | $3.4M | 0.1% | 0.4% | -89.7% |
| 25 | AAFMAA Wealth Management & Trust LLC | 24,721 | $2.7M | 0.9% | 0.3% | +5.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.